Indian molecular diagnostics company Genes2Me is gearing up for US market entry with its OnePCR sample-to-answer system, following CE marking of direct-from-blood assays for antimicrobial resistance and sepsis in Europe. The platform offers high multiplexing and large assay menus, detecting numerous pathogens in real-time PCR formats. Genes2Me has installed over 150 systems globally via distributors and is building commercial and technical teams in the Americas, Europe, and Asia. The company aims to meet rising global demand for integrated, cost-effective PCR diagnostics in infectious disease management.